The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

PR NewswireNov 21 23:46

Passage Bio Price Target Maintained With a $7.00/Share by Chardan Capital

Dow JonesNov 15 07:01 · Ratings

Passage Bio Is Maintained at Buy by Chardan Capital

Dow JonesNov 15 07:01 · Ratings

Express News | Vestal Point Capital LP Reports Passive Stake of 9.9% in Passage Bio as of September 30, 2024 - SEC Filing

BreakingsNov 15 01:04

Canaccord Genuity Maintains Buy on Passage Bio, Maintains $13 Price Target

Analyst UpgradesNov 15 00:12

Passage Bio Analyst Ratings

BenzingaNov 15 00:11 · Ratings